The Molecular Diagnostics Market DNA Probes And Biochips: Spain

I. INTRODUCTION

II. WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW

• A. DNA SEQUENCING
  • 1. Introduction
  • 2. Sequencing Methods
  • 3. Autoradiography
  • 4. The Human Genome Project
  • 5. Sequencing Automation
  • 6. Image Scanners
  • 7. Fluorescent Detection
  • 8. Gene Profiling
  • 9. Gene Expression
  • 10. Polymorphism Screening
  • 11. Protein Interaction Networks
• B. DNA AND RNA PROBE TECHNOLOGY
  • 1. Basic Principles
  • 2. Probe Preparation
  • 3. The DNA Probe Test
    • a. Sample Preparation
    • b. Hybridization
    • c. Separation
    • d. Detection/Measurement
  • 4. Test Formats
    • a. Filter Hybridization
    • b. Southern Blot
    • c. Northern Blot
    • d. In Situ Hybridization
    • e. Others
  • 5. Labeling Techniques
  • 6. Amplification Methods
    • * PCR
      • Temperature Cyclers
      • PCR Variations
    • * Immuno-PCR
    • * QC-PCR
    • * DAP-PCR
    • * SDA
    • *TMA
    • * LCR
    • * bDNA
    • * HPA
    • * NASBA
    • * 3SR
    • * Others
      • Ampliprobe
      • CAR
      • CAS
      • CPT
      • Dendritic Polymer Technology
      • ISO-CR
      • LAT
      • Probe Networks
      • RAMP
      • Repair Chain Reaction
      • Rolling Circles
      • Sequence Independent Gene
      • Amplification
      • Sequence Initiation Reaction
      • SISPA
• C. DETECTION TECHNOLOGIES
  • 1. Radioactive Methods
    • a. Overview
    • b. Major Isotopes
    • (P-32, S-35, H-3, I-125)
  • 2. Non-Isotopic Methods
    • a. Enzymatic
    • b. Chemical (Indirect, Direct)
    • c. Fluorescence
    • d. Chemiluminescence
    • e. Electrical Conductivity
• D. INSTRUMENTATION REVIEW
  • 1. Abbott LCx
  • 2. Autogenomics Infinity
  • 3. Beckman Coulter/Biomek FK
  • 4. Becton Dickinson SDA
  • 5. Bio-Rad GeneScope
  • 6. Gen-Probe Tigris
  • 7. Nanosphere Verigen Series
  • 8. Roche Cobas Amplicor
  • 9. Tecan LS Series
• E. BIOCHIPS:GENOSENSORS,MICROARRAYS, AND LABS-ON-THE-CHIP
  • Liquid Transportation and Mixing
  • Separation
  • Reaction
  • Detection
• F. PHARMACOGENOMICS
• G.MAJOR APPLICATIONS
  • 1. Microbiology/Infectious Diseases
    • a. Overview
    • b. Major Infectious Diseases
      • * AIDS
      • * Adenovirus
      • * Anthrax/Bacillus Anthracis
      • * Babesiosis
      • * BEA/Bartonella
      • * Chagas Disease
      • * Campylobacter
      • * Chlamydia
      • * Creutzfeldt-Jakob' s Disease
      • * Cytomegalovirus
      • * Ebola Virus
      • * EchoVirus
      • * Encephalitis
      • * Enteroviruses
      • * Epstein-Barr Virus
      • * Gonorrhea
      • * Hepatitis A, B, C, D, E, F, G
      • * Herpes Simplex Virus
      • * Legionella
      • * Lyme Disease
      • * Malaria
      • * Mycoplasma
      • * Papillomaviruses/HPV
      • * Parvovirus B19
      • * Pneumonia
      • * Polyomaviruses
      • * Salmonellosis
      • * Shigellosis
      • * Streptococci
      • * Toxoplasmosis
      • * Tuberculosis
      • *West Nile Virus
      • *Yersinia
    • c. Antibiotic Susceptibility
  • 2. Cancer Testing
    • a. Overview
    • b. Major Cancer Types
      • * Prostate
      • * Lung
      • * Colon and Rectum
      • * Breast
      • * Skin
      • * Uterine
      • * Leukemia
      • * Oral
    • c. Oncogenes
  • 3. Genetic Diseases
    • a. Overview
    • b. Nucleic Acid Amplification
    • c. Chromosome Imaging
    • d. Genomics Technologies
    • e. Proteomics Technologies
    • f. Current PharmacogenomicTest
    • g. Future Pharmacogenomic Testing
    • h. Major Diseases
      • * Achondroplasia
      • * Autosomal Dominant Polycystic Kidney Disease
      • * Cancer
      • * Cosmetogenomics
      • * Cystic Fibrosis
      • * Down' s Syndrome
      • * Duchenne and Becker Muscular Dystrophy
      • * Factor V (Leiden)
      • * Factor IX Deficiency
      • * Fragile X Syndrome
      • * Heart Disease
      • * Hemochomatosis
      • * Hemophilia
      • * Huntington' s Disease
      • * Maternal-Fetal Incompatibility
      • * Multiple Endocrine Neoplasia
      • * Phenylketonuria (PKU)
      • * Polycystic Kidney Disease
      • * Prenatal Screening
      • * Retinitis Pigmentosa
      • * Retinoblastoma
      • * Sickle Cell Anemia
      • * Spinal Muscular Atrophy
      • * Vitamin B12 Metabolism
    • i. Social Issues and Concerns
  • 4. Forensic Testing
    • a. Overview
    • b. Multilocus and Single Locus Probes
      • * Multilocus Probes
      • * Single Locus Probes
      • * PCR and RFLP
    • c. The FBI
    • d. DNA Profile Data Banks
      • * USA
      • * UK
    • e. Judicial Implementation
    • f. Major Crime Categories
    • g. Factors Contributing to the DNA Probe Market Expansion
      • * Technology Availability
      • * Use of Hair as Evidence
    • h. Wildlife Forensics
  • 5. Paternity Testing/HLA Typing
  • 6. Other Applications
    • a. Disease Susceptibility
    • b. Cardiovascular Diseases
    • c. Diabetes
    • d. Alzheimer' s Disease
    • e. Plasma Purification
    • f. Organ Transplantation
    • g. Water Contamination
    • h. Others
• G.COST ANALYSIS
  • 1. Equipment
  • 2. Consumables
• H.COMPETING/COMPLEMENTING TECHNOLOGIES
  • 1. Monoclonal Antibodies/Immunoassays
  • 2. RNA Probes
  • 3. 2D Electrophoresis
  • 4. Flow Cytometry
• I.REIMBURSEMENT ISSUES
• J.WORLDWIDE MARKET OVERVIEW
  • 1. Business Environment
  • 2. Market Structure
  • 3. Market Size and Growth

• A. EXECUTIVE SUMMARY
• B. BUSINESS ENVIRONMENT
• C. MARKET STRUCTURE
• D. MARKET SIZE, GROWTH AND MAJOR SUPPLIERS' SALES AND MARKET SHARES

X.MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

• A. INSTRUMENTATION
• B. REGEANT KITS AND TEST SYSTEMS/PANELS
• C. COMPUTERS, SOFTWARE AND AUTOMATION
• D. AUXILIARY PRODUCTS

XI. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

XII. ALTERNATIVE MARKET PENETRATION STRATEGIES

• A. INTERNAL DEVELOPMENT
• B. COLLABORATIVE ARRANGEMENTS
• C. UNIVERSITY CONTRACTS
• D. DISTRIBUTION STRATEGIES FOR DECENTRALIZED MARKETS
  • 1. Marketing Approaches
  • 2. Product Complexity
  • 3. Customer Preference
  • 4. Established Suppliers
  • 5. Emerging Suppliers
  • 6. Major Types Of Distributors
  • 7. Market Segmentation

XIII. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

• A. MARKET MATURITY
• B. COST CONTAINMENT
• C. COMPETITION
• D. TECHNOLOGICAL EDGE AND LIMITATIONS
• E. PATENT PROTECTION
• F. REGULATORY CONSTRAINTS
• G. DECENTRALIZED TESTING MARKET CHALLENGES

XIV. COMPETITIVE PROFILES

XV. APPENDIXES

• APPENDIX A: Major Companies Developing Or Marketing Molecular Diagnostic Reagents And Test Kits
• APPENDIX B: Major Universities and Research Centers Developing Molecular Diagnostic Technology
• APPENDIX C: Glossary of Terms
• APPENDIX D: Currency Exchange Rates Abbott

• Table II-1: Major Companies Developing or Marketing Thermocyclers
• Table II-2: Major Companies Developing or Marketing AIDS Molecular Diagnostic and Other Direct Identification Tests
• Table II-3: Major Companies Developing or Marketing Adenovirus Molecular Diagnostic and Other Direct Identification Tests
• Table II-4: Major Companies Developing or Marketing Campylobacter Molecular Diagnostic and Other Direct Identification Tests
• Table II-5: Major Companies Developing or Marketing Chlamydia Molecular Diagnostic and Other Direct Identification Tests
• Table II-6: Major Companies Developing or Marketing CMV Molecular Diagnostic and Other Direct Identification Tests
• Table II-7: Major Companies Developing or Marketing EBV Molecular Diagnostic and Other Direct Identification Tests
• Table II-8: Major Companies Developing or Marketing Gonorrhea Molecular Diagnostic and Other Direct Identification Tests
• Table II-9: Major Companies Developing or Marketing Hepatitis Molecular Diagnostic and Other Direct Identification Tests
• Table II-10: Major Companies Developing or Marketing Herpes Molecular Diagnostic and Other Direct Identification Tests
• Table II-11: Major Companies Developing or Marketing Legionella Molecular Diagnostic and Other Direct Identification Tests
• Table II-12: Major Companies Developing or Marketing Lyme Disease Molecular Diagnostic and Other Direct Identification Tests
• Table II-13: Major Companies Developing or Marketing Mycoplasma Molecular Diagnostic and Other Direct Identification Tests
• Table II-14: Major Companies Developing or Marketing Papilloma Molecular Diagnostic and Other Direct Identification Tests
• Table II-15: Major Companies Developing or Marketing Pneumonia Molecular Diagnostic and Other Direct Identification Tests
• Table II-16: Major Companies Developing or Marketing Salmonella Molecular Diagnostic and Other Direct Identification Tests
• Table II-17: Major Companies Developing or Marketing Shigella Molecular Diagnostic and Other Direct Identification Tests
• Table II-18: Major Companies Developing or Marketing Streptococci Molecular Diagnostic and Other Direct Identification Tests
• Table II-19: Major Companies Developing or Marketing Toxoplasmosis Molecular Diagnostic and Other Direct Identification Tests
• Table II-20: Major Companies Developing or Marketing Tuberculosis Molecular Diagnostic and Other Direct Identification Tests
• Table II-21: Major Companies Developing or Marketing Cancer Molecular Diagnostic Tests
• Table II-22: Major Companies Developing or Marketing Molecular Diagnostic Tests For Genetic Diseases
• Table II-23: Worldwide, Laboratories Performing DNA Sequencing by Country
• Table II-24: Worldwide, Molecular Diagnostics Market, Potential Laboratory Universe by Country
• Table II-25: Worldwide, Molecular Diagnostic Test Volume Forecast by Country
• Table II-26: Worldwide, Molecular Diagnostics Market Forecast by Country
• Summary Table: Spain, Molecular Diagnostic Test Volume and Sales Forecast by Major Application
• Table VII-1: Spain, Laboratories Performing DNA Sequencing by Market Segment
• Table VII-2: Spain, Molecular Diagnostics Market, Potential Laboratory Universe by Segment
• Table VII-3: Spain, Molecular Diagnostic Test Volume Forecast by Major Application
• Table VII-4: Spain, Major Infectious Diseases Molecular Diagnositic Test Volume Forecast by Assay
• Table VII-5: Spain, Infectious Disease Screening NAT Volume Forecast
• Table VII-6: Spain, Molecular Diagnostics Market Forecast by Major Application
• Table VII-7: Spain, Infectious Disease Screening NAT Market by Test
• Table VII-8: Spain, Molecular Diagnostics Market by Major Supplier
• Table VII-9: Spain, HIV/Hepatitis NAT Screening Market by Major Supplier